Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Binghe Xu et al.|Annals of Oncology|2021Cited by 724
Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?Gabriel A. Rabinovich, Stefano Iacobelli, Linda G. Baum et al.|Trends in Immunology|2002Cited by 530
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysisFrancesco Passiglia, Antonio Russo, Giuseppe Bronte et al.|Oncotarget|2016Cited by 166